Join us for our Edinburgh Medtech Forum where we bring together healthcare, medtech and healthtech professionals from around Edinburgh.
About this event
We kickstart 2024 in style with our next Edinburgh Medtech Forums event on 10th January.
We are excited to welcome Ben Panter, founder of Blackford Analysis, a purpose-built platform that simplifies the integration and management of AI applications and algorithms.
A University of Edinburgh spin-out, Blackford Analysis was acquired by the pharmaceuticals and consumer health leader Bayer UK in 2023. Join us to hear Blackford Analysis’ story, network with other members of the Edinburgh medtech community and enjoy some light refreshments.
If you are interested in Medtech and our future events, and are based in Edinburgh, please register here to be kept up to date with the Medtech Forums.
About our speaker | Ben Panter - Blackford Analysis:
Ben is the founder and CEO of Blackford Analysis. The company operates a platform business model in radiology, bringing together over a hundred 3rd party, regulatory cleared AI solutions and delivering them to healthcare providers and major OEM channel partners. The company’s deployed base covers over 6% of the US imaging market, with channel access to around 70% of the world market.
Ben's background is as an astronomer, where he developed a data processing technique that dramatically improved the speed of analysis of galaxy spectra. In combination with huge surveys of the night sky this approach gave unprecedented insight into the history of star formation in the Universe from the big bang to the present. He started Blackford with the wish to bring this data processing challenge to bear on a problem closer to home - that of medical imaging.
Founded in 2010 as a spin out from the University of Edinburgh, Blackford was acquired by Bayer Plc in Feb 2023, and continues to operate independently based on Bayer’s well-established ‘arm’s length’ operating model. Blackford remains accountable to advance the company’s technology, channel partnerships and clinical application portfolio while benefiting from the experience, infrastructure and reach of Bayer as a global pharmaceutical company.
This event is open to anyone interested in Medtech, but we’d particularly like to encourage the following to join us:
Allied healthcare professionals, including NHS colleagues
Primary care and acute hospital trusts
Biomedical and computer science students/graduates
Existing spin-outs from Universities or the NHS
Existing Medtech startups